Supplementary Figure 3
Tumor growth kinetics in response to RT in Kras-mutant murine NSCLC. Tumor volume kinetics of RT-treated tumors. Each line represents one mouse (n=5). Data of this cohort was previously published (Herter-Sprie et al., 2014) . 
Supplementary Figure 4
Tumor growth kinetics in response to RT and αPD-1 treatment in Kras/Lkb1-mutant murine NSCLC and differences in tumor-associated immune cell populations compared to Kras-mutant murine NSCLC. (A) CD45 + /EpCAM + ratio calculated from Figure 5B Figure  2B and Figure 5B ). (D) Expression of inhibitory T cell markers on CD8 + and CD4 + T cells of unirradiated Kras and Kras/Lkb1 tumors (taken from Figure 2E and Figure 5D ). Representative data are shown conducted with 5 unirradiated Kras, and 3 unirradiated Kras/Lkb1 mice (C and D). Data are represented as mean ± SEM. P values were calculated using two-tailed Student's t-test. *** P<0.001, ** P<0.01, * P<0.05. Table 1 List of murine antibodies used for flow cytometry analysis.
